<DOC>
	<DOCNO>NCT02118597</DOCNO>
	<brief_summary>This prospective , national , multicenter , non-interventional study examine use triple combination therapy boceprevir , pegylated interferon ( peginterferon ) alfa-2a ribavirin re-treating participant genotype 1 chronic hepatitis C ( CHC ) infection . Dosing treatment duration discretion investigator accordance local clinical practice local labeling . Participants observe duration triple combination therapy 24 week thereafter .</brief_summary>
	<brief_title>An Observational Study Examining Use Triple Combination Therapy With Boceprevir , Peginterferon Alfa-2a Ribavirin Re-Treatment Chronic Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>18 year age Genotype 1 CHC infection Prior unsuccessful treatment peginterferon alfa plus ribavirin ( nullresponse , partial response relapse participant ) Receiving triple combination therapy boceprevir , peginterferon alfa2a ribavirin accord standard care line local labeling Enrollment study later 4 week start triple combination therapy ( include peginterferon alfa2a ribavirin leadin phase ) Na√Øve participant respond peginterferon alfa plus ribavirin week 4 ( HCV RNA drop &lt; 1 log10 ) week 12 ( HCV RNA &gt; /= 15 international units/milliliter [ IU/mL ] ) switch triple combination therapy boceprevir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>